PipelineReview.com7h
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
CRANFORD, NJ, USA I January 7, 2025 I Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, ...
PipelineReview.com7h
Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i
NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
PipelineReview.com7h
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk to Discover Novel Targets for Metabolic Disease
SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo ...
PipelineReview.com7h
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...
PipelineReview.com7h
BrainChild Bio, Inc. to Clinically Advance BCB-276, an Autologous B7-H3 Targeting CAR T-cell Therapy for Incurable Pediatric Brain Tumors
The Company has aligned on clinical plan based on a positive FDA meeting, leveraging clinical data from a first-in-human Phase 1 trial published today in ...
PipelineReview.com7h
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...